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Abstract
Probiotic bacteria are live microorganisms which confer to health benefits of the host. They help to maintain the
integrity of the intestinal barrier function by modulating the mucosal and systemic immune response of the host.
These bacteria have proven their beneficial effect in several conditions of ulcerative colitis. More recently
probiotics/synbiotics have been included in the treatment of critically ill patients. However to date it remains
uncertain whether probiotics/synbiotics are beneficial or even dangerous to the clinical outcome of this patient
group. This article reviews the current evidence of the use of bacteria in critically ill patients in intensive care
settings.
Introduction
Severe sepsis with associated multisystem organ dys-
function is a leading cause of death in patients hospita-
lized in intensive care units (ICU). The gastrointestinal
tract plays an important role in the pathogenesis of mul-
tiorgan dysfunction owing to a breakdown of intestinal
barrier function and increased translocation of bacteria
and bacterial components into the systemic circulation.
During critical illness, alterations in gut microflora are
due to several factors that include changes in circulating
stress hormones, gut ischemia, immunosuppression, the
use of antibiotics and other drugs, possible bacterial
translocation and the lack of nutrients [1]. In experi-
mental models of pancreatitis, it has been demonstrated,
that Lactobacillus strains disappear after 6 to 8 hours
from the gut and are replaced by an overgrowth of
pathogenic bacteria [2]. The importance of endogenous
strains of probiotic bacteria such as Bifidobacterium and
Lactobacillus in maintaining intestinal barrier function
by modulating mucosal and systemic immune responses
is becoming evident from numerous studies [3]. Also
the airways can be colonized by pathogens, due to
broad-spectrum antibiotic use, reduction in gastric pH
as part of the stress ulcer prophylaxis, and the impair-
ment of mucosal defense mechanisms due to trauma
induced by indwelling endotracheal or nasogastric tubes
[4]. In fact, ventilator associated pneumonia (VAP)
occur in 9-27% of patients maintained on mechanical
ventilation for more than 48 h. VAP is associated with a
mortality of 10-40%, increased ICU and hospital stay
and an estimated cost of between US$ 12.000 to US$
16.000 per episode [5,6]. Thus, interest has been devel-
oped in utilizing probiotics as colonizers to prevent the
cycle of colonization with pathogens and ultimately
nosocomial infections [7]. Thus the therapeutic concept
with probiotics is an effort to reduce or eliminate poten-
tial pathogens and toxins, to release nutrients, antioxi-
dants, growth factors and coagulation factors, to
stimulate gut motility and to modulate innate and adap-
tive immune defense mechanisms via the normalization
of altered gut flora [8].
Currently bacteria in synbiotic (prebiotic and probiotic
components) and probiotic preparations are being used
experimentally in the treatment of acute pancreatitis,
liver transplantations, inflammatory bowel disease, acute
and infectious diarrhea and trauma patients [9].
Properties of Probiotics
Probiotics are, according to the FAO/WHO “live bac-
teria which when administered in adequate amounts
confer a health benefit to the host”. These bacteria do
not contain any virulence properties or antibiotic resis-
tance cassettes. They create an unfavourable environ-
ment for pathogens by mechanisms including
promotion of the integrity of the guts defense barrier by
normalizing intestinal permeability, modulation of
intestinal secretory immunoglobulin function, control of
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intestinal inflammatory responses and by balancing the
release of cytokines. In addition, probiotics maintain
normal microecology of the gastrointestinal flora and
antimicrobial effects mediated by nutrient competition,
alteration of local pH, production of bacterocins, modifi-
cation of pathogen derived toxins and stimulation of
epithelial mucin production [7]. Numerous microorgan-
isms (see Table 1 and Table 2; e.g. Lactobacillus rham-
nosus GG, L. reuteri, bifidobacteria and certain strains of
L. casei or the L. acidophilus-group) are used in probio-
tic food, particularly fermented milk products, or have
been investigated–as well as Escherichia coli strain Nis-
sle 1917, certain enterococci (Enterococcus faecium
SF68) and the probiotic yeast Saccharomyces boulardii–
with regard to their medicinal use. A well studied syn-
biotic is the preparation Synbiotic 2000 Forte. It con-
tains the bacteria Pedicoccus pentasacceus, Leoconostoc
mesenteroides, Lactobacillus paracasei subsp. paracasei
and Lactobacillus plantarum (at a dose of 1010 bacteria
per sachet) as probiotics and betaglucan, inulin, pectin
and resistant starch as prebiotics [5]. VSL#3 (VSL Phar-
maceutical, Gaithersburg, Maryland) is a probiotic pre-
paration containing live freeze- dried lactic acid bacteria
containg approximately 450 billion bacteria in defined
ratios of lyophilized Bifidobacterium breve, B. longum,
B. infantis, L. acidophilus, L. plantarum, L. casei, L. bul-
garicus and Streptococcus thermophilus Since probiotics
are staying only transiently in the gut they have to be
ingested every day. This is crucial as most antibiotic
treatments will kill the probiotic bacteria [3].
Basic mechanisms of probiotics
During periods of critical illness, significant alterations
occur in the gut microflora. Reasons for this are changes
in circulating stress hormones, gut ischemia, the use of
immunosuppressive drugs, antibiotics and the lack of
adequate nutrients. Several studies have shown that cer-
tain probiotic bacteria are able to maintain the intestinal
barrier function und to modulate the mucosal and
intestinal immune function [3]. Probiotics may also
reduce the incidence of VAP via a combination of local
and systemic effects resulting in decreased colonisation
[4]. The mechanisms are local and systemic. Local
effects include reduced overgrowth of potential patho-
gens by competitive inhibition and direct antimicro-
bial effects. Secondary systemic benefits may result
from improved gut mucosal barrier function, reduced
bacterial translocation and upregulation of immune
function [5,10,11]
Based on these properties of probiotics, several studies
were conducted in the critical ill patients. We have con-
ducted a PubMed search with the terms “Probiotic” and
“Intensive care unit”. We received 75 “hits” (end of Dec.
2010) and here we will present the most notable studies
[Table 1 and Table 2].
Evidence for no or negative effects on the outcome of
critical ill patients
Jain and colleagues (2004) [11] demonstrated in a double-
blind, randomized and placebo controlled study a “favour-
able” change in the colonization of gastric contents in
45 ICU patients treated with synbiotic preparation (4 ×
109 of Lactobacillus acidophilus, Bifidobacterium lactis,
L. bulgaricus, Streptococcus thermophilus) in comparison
of 45 ICU patients receiving a placebo. Even though there
was a significant difference in the number of aspirates
with multiple organisms cultured (39% versus 75%) as well
as the number of potentially pathogenic organisms (43%
versus 75%) identified in the synbiotic group when com-
pared to placebo, there were no significant differences
between the two groups in the secondary outcomes of
septic complications, mortality, days in ICU, days of hospi-
talization and respiratory complications.
No significant changes in cultures of the NGT aspi-
rates and no significant differences with regard to intest-
inal permeability, CRP levels, septic morbidity and
mortality or days in the ICU was reported in another
study [12] with a preparation of L. plantarum 299v
Table 1 List of studies mentioned with no or negative effects of probiotics on critically ill patients
Study Study design Number of patients Probiotics/Synbiotics Results
Jain et al. [11] double-blind,
randomized,
placebo-control.
90 ICU patients: 45
verum vs 45 placebo.
4 × 109 of Lact. acidophilus, Bifid. lactis, L.
bulgaricus, Strept. thermophilus +7,5 g
Oligofructose.
less potentially pathogenic bact. no







103 critical lll: 51
verum vs 52 placebo.
L. plantarum 299v + oatmeal + fruit drink. no differences: intestinal permeability,
CRP level morbidity + mortality.













167 ICU patients: 84
verum vs 83 placebo.
2 × 1010 Lact. rhamnosus GG. no differences: mortality, ICU acquired
infections.
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(nonblinded, randomized, non placebo controlled study).
However there was a significant difference in favour of
the probiotic of IL-6 levels compared to control.
Olah and colleagues (2007) [13] used in their double-
blind, randomized and placebo controlled study a high
CFU synbiotic product Synbiotic 2000 Forte in 62 patients
with severe acute pancreatitis. There were no statistical
significant differences in the incidence of mortality, septic
complications or development of multiorgan failure
between the groups. However, the total incidence of SIRS
and multiple organ failure was significantly different
between the two groups (8 vs. 14). In addition, the rate of
complications was significantly less in the verum group.
In a most recent study, Barraud and colleagues (2010)
[14] conducted a double-blind, randomised and placebo-
controlled trial to assess the effects of prophylactic pro-
biotic administration in patients on mechanical ventila-
tion. A total of 167 patients were included, half of these
received 2 × 1010 Lactobacillus rhamnosus GG. The 28
day mortality rates were not different in the probiotic
(25,3%) and placebo groups (23,7%). The incidence of
ICU-acquired infections did not differ significantly
except for that of catheter related bloodstream infec-
tions that was lowered by probiotics.
Evidence for positive effects on the outcome of critical ill
patients
Alberda and colleagues (2007) [15] demonstrated a signifi-
cant increase in IgG and IgA levels in favour of the live
synbiotics (preparation of 9 × 1011 L. casei, L. plantarum,
L. acidophilus, L. delbrueckii, Bifidobacterium longum,
B. breve, B. infantis, Streptococcus salivarius) over devita-
lized synbiotics or placebo in 28 ICU patients (double-
blind, randomized, placebo controlled study).
Spindler-Vessel and colleagues (2007) [16] were able
to demonstrate a significant reduction in infectious
pneumonias (19% versus 53%), intestinal permeability,
and procalcitonin levels in 113 trauma ICU patients
with the use of a symbiotic preparation (1010 of P. pen-
tosaceus, 1010 L. paracasei, 1010 L. plantarum). This
study was however nonblinded, randomized, nonplacebo
controlled.
Olah and colleagues (2002) [17] performed a rando-
mized double-blind study in 45 patients with acute pan-
creatitis. Significant results were demonstrated in favour
of the live synbiotic (109 L plantarum 299) for septic
complications requiring surgery (5% versus 30%) and
positive pancreatic aspiration cultures (5% versus 30%).
However there were no significant differences in respira-
tory infections, rates of multiple organ failure, days of
hospital stay, mortality, CRP levels, rates of necrotizing
pancreatitis or positive blood cultures.
Forestier and colleagues (2008) [18] conducted a pro-
spective, randomized, double-blind, placebo controlled
pilot study with 208 patients on an ICU unit, with a
stay longer than 48 hours. Through a nasogastric feed-
ing tube patients received either 109 CFU Lactobacillus
casei/rhamnosus or placebo twice daily. The authors
Table 2 List of studies mentioned with positive effects of probiotics on critically ill patients
Study Study design Number of patients Probiotics/Synbiotics Results
Alberda et al. [15] double-blind,
randomized,
placebo-control.
28 ICU patients: 14
verum vs 14
placebo.
9 × 1011 L. casei, L. plantarum, Strept. salivarius,
B. infantis L. acidophilus, B. longum, L. delbrueckii,
B. breve.







113 ICU trauma pat.:
87 verum vs 26
placebo.
1010 of P. pentosaceus, 1010 L. paracasei,1010 L.










109 L plantarum 299 vs heat killed bacteria +10
g oat fibre.
less septic complications in
verum group.
Forestier et al. [18] double-blind,
randomized,
placebo-control.
208 ICU patients: 104
verum vs104
placebo.
109 Lact. rhamnosus, 109 Lact. casei. P. aeruginosa colonization +







pat.:32 verum vs 33
placebo.
Synbiotic 2000 Forte. reduced rate of infection, SIRS,
severe sepsis + mortality in
verum.
Klarin et al. [20] nonblinded,
randomized,
nonplacebo.
44 ICU patients: 22
verum vs 22
109 Lact. plantarum 299v + oatmeal. colonisation of C. difficile not
detectable in verum group.
Morrow et al. [21] double-blind,
randomized,
placebo-control.
146 ICU patients: 73
verum vs 73
placebo.
1010 Lact. rhamnosus GG109 Lact. casei. development of VAP less likely +






45 ICU patients: 20
verum vs 25
placebo.
VSL#3. effective in reducing frequency
of liquid stool.
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showed that the occurrence of P. aeruginosa respiratory
colonization and/or infection was significantly delayed
in the probiotic group with differences in median delay
to acquisition of 11 versus 50 days.
In another double-blind, placebo controlled trial the
benefits of a Synbiotic 2000 Forte treatment was investi-
gated on the rate of infections, SIRS, severe sepsis and
mortality in critical ill patients. 65 patients were rando-
mized to receive once daily for 15 days the synbiotic
formulation. These patients exhibited a significant
reduced rate of infections (63% versus 90%), SIRS,
severe sepsis and mortality (14% versus 22%) in compar-
ison to the placebo group [19].
The incidence of Clostridium difficile-associated diar-
rhoe (CDAD) in hospitalised and especially critical ill
patients is increasing because of the wide use of antibio-
tics. In a Swedish study, 22 ICU patients were given the
probiotic bacterium L. plantarum while 22 other
patients received a placebo. 19% of the placebo group
were colonised with C. difficile, while none were colo-
nised who received the probiotic [20].
In a study which was published last year, Morrow and
colleagues [21] elucidated if the use of Lactobacillus
rhamnosus GG can reduce the incidence of VAP. They
randomized 146 patients (prospective, double-blind and
placebo-controlled study) and found that patients trea-
ted with the bacteria were significantly less likely to
develop a VAP when compared to patients treated with
a placebo. Also patients had significantly less CDAD
than placebo treated patients (18,6% versus 5,8%) even
though the duration of the diarrhoe was not different
between the groups.
In a pilot trail with the probiotic mixture VSL#3 Froh-
mader and colleagues [22] described the effectiveness of
these bacteria in reducing the frequency of liquid stool
in critically ill patients receiving enteral nutrition. In
this single center, double-blind, randomized and placebo
controlled study the group included 45 adults (20 verum
vs 25 placebo). The verum group had a significant
reduction in the frequency of liquid stool (0.27 vs 0.93;
P = 0.03).
Conclusions
The use of probiotic or synbiotic preparations in criti-
cally ill patients continues to be controversial. However,
we found fewer publications reporting no or negative
effects on the use of probiotics in critical ill patients,
than the number of publications presenting positive
effects [Table 1 and Table 2].
The problem we are facing is that most of the current
literature is limited by poor trial design, small study
samples, poorly defined endpoints and a great variety of
often poorly defined mixtures of probiotics. Additionally,
the number of probiotic bacteria ingested by the
patients vary up to a hundredfold from study to study.
Studies were always from single centers and some of the
results were rather weak; Olah et al [13] reported that
the lower incidence of multiorgan failure, septic compli-
cations and mortality was not significant but the total
incidence of SIRS and multiorganfailure was significantly
different between the groups. Basically the studies
included three different groups of patients; patients with
acute pancreatitis, trauma patients and patients being
admitted to the ICU with a whole range of severe medi-
cal problems (eg cardiac, respiratory). Because of the
limited number of patients and the different probiotic
preparations and the different endpoints (e.g. reducing
rate of infection, SIRS, procalcitonin levels, development
of VAP or CDAD), unfortunately, it is not possible to
break down which group of patients will benefit most
from the use of probiotics.
Well designed multi center studies with a defined
mixture of bacteria, for example Synbiotic 2000 Forte,
on a defined group of critically ill patients are essential
before any conclusion on the effect of probiotics/synbio-
tics can be drawn. In addition, the endpoints have to be
clearly defined. Clinical work is one step, but similarly
important is the research on the bench to elucidate the
exact mechanisms by which probiotic strains elicit their
effects in the host organism. Once we understand these
mechanisms then we might even go a step further to
improve the properties by using “patho-biotechnology”.
Essentially, this novel approach involves the generation
of “improved” probiotic strains, transforming them with
stress survival systems from other microbes. A good
example is cloning and heterologous expression of a sin-
gle bile resistance gene from the food borne pathogen
Listeria monocytogenes in the probiotic strain Bifidobac-
terium breve, not only improves gastrointestinal coloni-
sation and persistence, but also significantly bolsters the
clinical efficacy of the probiotic strain. In addition,
‘designer probiotics’ have been engineered to express
receptor-mimic structures on their surface. When admi-
nistered orally these probiotics bind to and neutralize
toxins in the gut lumen and interfere with pathogen
adherence to the intestinal epithelium - thus essentially
preventing the infection. In this situation is the use of
antibiotics unnecessary, circumventing the problems
with antibiotic resistance [23,24].
In conclusion, we have not yet enough data to firmly
support the use of probiotic bacteria in the setting of
intensive care units. Well designed multi center clinical
studies with defined mixtures of probiotics and defined
endpoints are warranted in this field.
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